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ABSTRACT
Objective: Proteinuria is an established risk factor for progressive damage of kidney. This proteinuria can be effectively controlled by drugs 
that interrupt the renin–angiotensin–aldosterone system. However, the efficacy of N-acetyl cysteine (NAC) and taurine in prevention of diabetic 
nephropathy (DN) is uncertain. The role of NAC and taurine in reducing of proteinuria in patients with DN was studied.
Methods: The present study was undertaken in the Postgraduate Department of Medicine of S.N. Medical College, Agra. A total of 60 patients of 
diabetes mellitus with evidence of nephropathy were included in the study. Twenty patients were given placebo medication (Group P), 20 patients 
received NAC (Group A), and remaining 20 received a combination of NAC and taurine (Group B). Each group was further subdivided according to 
the urinary albumin excretion in 24 hrs. Subgroup 1 - Urinary albumin excretion between 30 and 300 mg/24 hrs. Subgroup 2 - Urinary albumin 
excretion >300 mg/24 hrs. The stastical analysis used Student’s t-test.
Results: On comparison, in both microalbuminuria and macroalbuminuria patients divided into three groups; the difference in magnitude of increase 
in proteinuria (after NAC, NAC with taurine, and placebo administration) over 24 weeks of the study period was statistically insignificant.
Conclusions: In this study, there was no significant difference of proteinuria before and after NAC administration, and also in our study, there was no 
significant difference of proteinuria before and after taurine administration.
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INTRODUCTION
Diabetic nephropathy (DN) is the leading cause of mortality and 
morbidity in diabetic patients. It is also the leading cause of end-stage 
renal disease (ESRD). The proportion of diabetes-related ESRD among 
all cases of ESRD is reported to be about 25-55%. The pathological 
abnormality found in DN includes mesangial expansion, basement 
membrane thickening, glomerulo- and arteriosclerosis, changes in 
endothelial and tubular cells, podocyte abnormalities, and interstitial 
inflammation [1-3]. However, the excessive deposition of extracellular 
matrix (ECM) proteins in mesangium and basement membrane 
of glomerulus are the earliest morphological changes and typical 
hallmarks of DN [4,5].
The earliest clinical evidence of DN is microalbuminuria [6]. Glomerular 
hemodynamic changes such as hyperperfusion and hyperfiltration cause 
leakage of albumin from glomerulus into Bowman’s space [7]. There are 
many factors including nitric oxide (NO), insulin-like growth factors, 
angiotensin II, vascular endothelial growth factor, transforming growth 
factor β1 (TGF β1), cytokines, and reactive oxygen species (ROS) have been 
implicated in pathogenesis of DN. Hyperglycemia induces endothelial 
apoptotic cell death and vascular endothelial dysfunction (VED) [8]. 
More precisely, hyperglycemia leads to production of ROS, which in turn 
causes downregulation of expression of NO synthase [8]. VED results in 
decreased production of NO and increased production of ROS. It is well 
known that blockage of renin angiotensin aldosterone system prevents 
microalbuminuria progression and ultimately chronic renal damage [9].
Oxidative stress is a well-known phenomenon in pathogenesis of DN. It 
has been seen that antioxidants such as vitamin E, vitamin C, and statins 
reduce proteinuria in diabetic patients. Human studies on N-acetyl 
cysteine (NAC) as an antioxidative agent are limited; the majority of 
studies are on animal models. NAC in experimental models has revealed 
a reduction in ischemia in acute kidney damages, improved glomerular 
filtration rate, and shortened recovery periods [10-13]. Studies of 
human beings on the role of NAC in the treatment of DN and proteinuria 
are not frequent and findings are controversial [14-17].
Taurine (2-aminoethanesulfonic acid) is considered an endogenous 
antioxidant. Recent studies have shown that taurine protects renal 
tissues against damage from oxidative stress [18-21]. To further 
investigate, we studied the therapeutic efficacy of NAC and taurine in 
proteinuria in DN.
METHODS
The present study was undertaken in the Postgraduate Department of 
Medicine of S.N. Medical College, Agra. A total of 60 patients of diabetes 
mellitus with evidence of nephropathy were included in the study. 
Patients with known hypersensitivity to NAC/taurine, with chronic 
liver disease, patients with non-diabetic nephrotic cause of proteinuria, 
patients with acid peptic disease, pregnant and lactating women, 
patients with uncontrolled hypertension, patients with coronary artery 
disease, patients who have had cerebrovascular accident within last 
1 year, patients with evidence of heart failure, and patients taking 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers (ARBs), and calcium channel blockers were excluded from the 
study. Ethical clearance was taken from Ethical Committee. After taking 
informed consent, three groups were made according to medication 
used. Twenty patients were given placebo medication (Group P), 
20 patients received NAC (Group A), and remaining 20 received a 
combination of NAC and taurine (Group B).
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• Group P - Received placebo
• Group A - Received NAC
• Group B - Received combination of NAC and taurine.
Each group was further subdivided according to the urinary albumin 
excretion in 24 hrs.
• Subgroup 1 - Urinary albumin excretion between 30 and 300 mg/24 hrs
• Subgroup 2 - Urinary albumin excretion >300 mg/24 hrs
The enrolled patients were subjected to detailed clinical examination. 
Cases were subjected to the following investigations:
Hemogram, blood sugar (fasting and postprandial), kidney function 
test, liver function test, urine analysis, 24 hrs urine protein, fundus 
examination, ultrasonography for kidney size, and echogenicity. 
Patients were followed up at 24 weeks. Tight glycemic control was 
maintained in all groups, and drug compliance was assured.
RESULTS
A maximum number of cases were in the age group of 46-55 years 
(Table 1).
There is male preponderance in all the three groups. This can be 
explained by as males are attending the outpatient department more 
than females in numbers (Table 2).
In patients with microalbuminuria and receiving placebo drug (Group P1), 
mean baseline value of microalbuminuria was 222.25±66.25 mg/24 hrs, 
and at 24 weeks, it was 251.50±55.58 mg/24 hrs. Percentage increase 
in mean value of microalbuminuria at 24 weeks from baseline (13.16%) 
was significant. In patients with microalbuminuria and receiving 
NAC (Group A1), the mean baseline value of microalbuminuria was 
209.86±64.32 mg/24 hrs, and at 24 weeks, it was 229.29±60.52 mg/24 
hrs. Percentage increase in value at 24 weeks was 9.26% and that 
was significant. In Group B1, in which the patients were receiving a 
combination of NAC and taurine, mean baseline microalbuminuria was 
225.67±49.60 mg/24 hrs, and at 24 weeks, it was 244.33±53.61 mg/24 
hrs. Percentage increase in mean value of the albuminuria as compared 
to baseline value was 8.27% and this increase in mean value was 
significant (Table 3).
At 24 week, comparison of decrease in magnitude of microalbuminuria 
in all three groups (P1, A1, and B1) was insignificant statistically.
In patients with overt proteinuria receiving placebo (Group P2), 
mean baseline value was 609.67±147.03 mg/24 hrs and at 24 weeks 
was 657.33±154.20. The percentage increase in overt proteinuria at 
24 weeks was 7.82%. This increase in proteinuria was significant at 
24 weeks. In patients with overt proteinuria receiving NAC (Group A2), 
mean baseline value was 628.67±200.83 mg/24 hrs and 24 weeks 
was 671.83±222.55. The percentage increase in overt proteinuria 
at 24 weeks was 6.87%. In patients with overt proteinuria receiving 
a combination of NAC and taurine (Group B2), mean baseline value 
was 642.75±205.53 and at 24 weeks was 685±218.57 mg/24 hrs. 
Table 1: Age distribution of cases
Age range (in years) Group P Group A Group B
25-35 2 2 0
36-45 7 8 8
46-55 8 10 12
56-65 3 0 0
Total 20 20 20
Table 2: Sex distribution of cases
Sex N (%)
Group P Group A Group B
Male 12 (60.00) 15 (75) 14 (70)
Female 8 (40.00) 5 (25) 6 (30)
Total 14 (100) 26 (100) 20 (100)
Table 3: Microalbuminuria at baseline and 24 weeks (Subgroup 1 in all these groups)
Group Subgroup Number 24 hrs proteinuria 
baseline (mg/24 hrs)
24 hrs proteinuria at 
24 weeks (mg/24 hrs)
% change over baseline
P 1 11 222.25±66.25 251.5±55.58 13.16
A 1 8 209.86±64.32 229.29±60.52 9.26
B 1 12 225.67±49.60 244.33±53.61 8.27
Subgroups 1 24 hrs proteinuria baseline (mg/24 hrs) 24 hrs proteinuria at 24 weeks (mg/24 
hrs)
t‑value p value t‑value p value
Groups P and A 0.4093 0.4093NS 0.8282 0.421NS
Groups P and B −0.1392 0.8908NS 0.3275 0.7466NS
Groups A and B −0.5883 0.5669NS −0.5695 0.5781NS
NS: The two samples are not significantly different
Table 4: Overt albuminuria/24 hrs at baseline and at 24 weeks (Subgroup in all these groups)
Group Subgroup N Baseline 
proteinuria (mg/24 hrs)
Proteinuria at 
24 weeks (mg/24 hrs)
% Change over baseline
P 2 9 609.67±147.03 657.33±154.20 7.82
A 2 12 628.67±200.83 671.83±222.55 6.87
B 2 8 642.75±205.53 685.00±218.57 6.57
Subgroups 2 Proteinuria baseline (mg/24 hrs) Proteinuria at 24 weeks (mg/24 hrs)
t‑value p value t‑value p value
Group P and A −0.2351 0.8166NS −1762 0.862NS
Group P and B −0.3774 0.7122NS −0.2981 0.7705NS
Group A and B −0.1515 0.8816NS −0.1311 0.8974NS
NS: The two samples are not significantly different
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The percentage increase at 24 weeks was 6.57%. This increase in 
proteinuria was significant at 24 weeks.
On comparing, decrease in overt albuminuria at 24 weeks in each group 
(P2, A2, and B2) was statistically insignificant (Table 4).
DISCUSSION
It is well established that ACE inhibitors and ARBs halt the progression 
of proteinuria in diabetic patients. Studies have shown that oxidative 
stress leads to progression of glomerulonephritis by producing 
nicotinamide adenine dinucleotide phosphate oxidase [20,21]. NAC has 
considerable effects on free radicals and oxidative stress. Plasminogen 
inhibitors have a role in ECM fixing. Hyperglycemia promotes 
plasminogen inhibitors and induces free radicals. This phenomenon 
damages glomeruli in diabetic patients. Lee et al. in their study have 
shown that NAC reduces plasminogen inhibitor levels and decreases 
free oxygen radicals [22]. Trend toward using NAC due to its antioxidant 
role has been increasing [23]. Clinically, only one study has been done 
to demonstrate the therapeutic effects of NAC on proteinuria in diabetic 
patients [24]. In this study, there was no significant difference of 
proteinuria before and after NAC administration.
In a study on diabetic rats, taurine, an endogenous antioxidant, has 
suppressed further increase in urinary protein excretion. In this 
study, it was also seen that taurine reduced mesangial extracellular 
matrix expansion and TGF β expression in renal glomeruli. TGF β has 
been postulated to play an important role in mesangial expansion by 
accelerating ECM production in diabetic renal tissues. Studer et al. [25] 
had shown that taurine inhibited high glucose-related overexpression 
of TGF β in cultured mesangial cells in similar fashion to that of NAC. 
Evidence of beneficial effects of taurine in DN has been accumulating. 
Ha et al. [19] reported that taurine suppresses the expression of TGF β 
at both mRNA and protein levels. Furthermore, Trachtman et al. [21] 
showed that taurine decreases immunohistochemical staining of 
Type IV collagen in glomeruli of diabetic rats. However, in our study, 
there was no significant difference of proteinuria before and after 
taurine administration.
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